What is it?
It’s a fluocinolone acetonide intravitreal implant.

Who is it for?
It’s approved for patients with chronic noninfectious posterior uveitis.

Tell me more about the implant.
It uses the Durasert drug delivery technology which allows for sustained-release delivery of small molecules for up to three years with a single injection. Yutiq is designed to release consistently over 36 months.

What about the clinical trials?
There were two phase 3 trials and in both trials, there was a significant reduction in uveitis recurrence in patients treated with Yutiq as compared to sham. The most common adverse reactions reported were cataract development and increase in IOP. (viavia)